Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader
- Category: Small Molecules
- Published on Wednesday, 28 August 2019 11:04
- Hits: 978
Trial is evaluating the safety and tolerability of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer
NEW HAVEN, CT, USA I August 27, 2019 I Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-471, an oral estrogen receptor (ER)-targeting PROTAC® protein degrader, will evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. Arvinas anticipates preliminary data from the trial in 2020.
“ARV-471 is a potent ER degrader that has demonstrated significant anti-tumor activity in preclinical models, and we are hopeful it will address an important need for patients with advanced ER positive breast cancer not adequately treated with current standards of care,” said Ronald Peck, M.D., Chief Medical Officer of Arvinas. “ARV-471 is Arvinas’ second targeted protein degrader to enter the clinic, making this another exciting and significant development for our company and the field.”
The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of ARV-471 and will include measures of its pharmacodynamic and anti-tumor activity as secondary endpoints. In preclinical studies, orally administered ARV-471 demonstrated improved in vivo ER degradation potency and anti-tumor activity both as a monotherapy and in combination with a CDK4/6 inhibitor, as compared to current standard of care treatment regimens. In future trials, the company plans to investigate ARV-471 for use as both a single agent and in combination with other modalities, such as CDK 4/6 inhibitors. Additional information on this clinical trial can be found on www.clinicaltrials.gov.
About locally advanced or metastatic ER positive / HER2 negative breast cancer
In the United States, breast cancer is the second most common cancer and the second leading cause of cancer death in women. The American Cancer Society estimates that there will be approximately 268,000 women diagnosed with invasive breast cancer in the U.S. in 2019. Metastatic breast cancer accounts for approximately 6% of newly diagnosed cases. Approximately 80% of newly diagnosed breast cancers are ER+, with many patients developing resistance to current treatment options over time.
Women with locally advanced or metastatic breast cancer are treated with systemic therapies, including hormone therapy, chemotherapy, and targeted therapy, either as single agents or in combination. Women with metastatic or recurrent ER positive breast cancer are often treated with hormone therapy, such as tamoxifen, an aromatase inhibitor, or fulvestrant, alone or in combination with targeted drugs such as CDK 4/6 inhibitors. In patients with aggressive disease or whose disease continues to progress with hormonal treatment regimens, chemotherapy may be prescribed.
A current standard of care for women with ER positive locally advanced or metastatic breast cancer is fulvestrant, which is administered as a monthly intramuscular injection, either as a single-agent or in combination with another targeted therapy. While fulvestrant has validated the importance of ER degradation as a therapeutic intervention, up to 50% of ER can remain when compared to baseline levels after six months of treatment with fulvestrant.
ARV-471 is a PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER). Arvinas’ Phase 1 trial of ARV-471 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.
In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity as a single agent and in combination with a CDK4/6 inhibitor when compared to a standard of care agent, fulvestrant (as a single agent and in combination with a CDK4/6 inhibitor). Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis-targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company’s initial clinical program, ARV-110 for the treatment of patients with metastatic castrate-resistant prostate cancer, began a Phase 1 clinical trial in the first quarter of 2019. The Investigational New Drug application (IND) for ARV-471, in development for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer, was cleared by the U.S. Food and Drug Administration (FDA) in the second quarter of 2019. For more information, visit www.arvinas.com.